Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. trimmed its holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 7.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,080 shares of the biotechnology company’s stock after selling 773 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Arcturus Therapeutics were worth $316,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. ARK Investment Management LLC increased its stake in shares of Arcturus Therapeutics by 7.7% in the fourth quarter. ARK Investment Management LLC now owns 2,047,687 shares of the biotechnology company’s stock worth $64,564,000 after buying an additional 146,141 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Arcturus Therapeutics by 11.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,088,930 shares of the biotechnology company’s stock worth $34,336,000 after purchasing an additional 115,087 shares during the last quarter. FMR LLC raised its stake in shares of Arcturus Therapeutics by 8.6% in the 3rd quarter. FMR LLC now owns 940,281 shares of the biotechnology company’s stock valued at $24,024,000 after purchasing an additional 74,081 shares in the last quarter. Jupiter Asset Management Ltd. bought a new position in shares of Arcturus Therapeutics during the third quarter worth about $4,977,000. Finally, Charles Schwab Investment Management Inc. grew its stake in Arcturus Therapeutics by 1.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 186,310 shares of the biotechnology company’s stock worth $5,874,000 after purchasing an additional 2,369 shares in the last quarter. 94.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ARCT. William Blair reaffirmed an “outperform” rating on shares of Arcturus Therapeutics in a report on Friday, March 8th. Canaccord Genuity Group reduced their price objective on Arcturus Therapeutics from $87.00 to $86.00 and set a “buy” rating on the stock in a research note on Friday, May 10th. Citigroup boosted their target price on shares of Arcturus Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a research note on Thursday, February 8th. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of Arcturus Therapeutics in a report on Wednesday, March 20th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $64.86.

Arcturus Therapeutics Price Performance

Shares of NASDAQ ARCT opened at $32.38 on Thursday. Arcturus Therapeutics Holdings Inc. has a 1-year low of $17.52 and a 1-year high of $43.81. The firm has a market capitalization of $872.06 million, a PE ratio of -8.28 and a beta of 2.65. The business’s fifty day moving average price is $30.30 and its two-hundred day moving average price is $30.82.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($1.69) by $1.37. Arcturus Therapeutics had a negative net margin of 81.59% and a negative return on equity of 37.61%. The firm had revenue of $33.99 million for the quarter, compared to the consensus estimate of $64.14 million. Equities research analysts expect that Arcturus Therapeutics Holdings Inc. will post -4.39 earnings per share for the current fiscal year.

Insider Activity

In related news, COO Pad Chivukula sold 17,435 shares of the stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $35.02, for a total value of $610,573.70. Following the completion of the transaction, the chief operating officer now directly owns 473,448 shares of the company’s stock, valued at approximately $16,580,148.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 13.80% of the company’s stock.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.